United Therapeutics Corp
UTHR
$548.27
-0.24%
United Therapeutics Corp is a biotechnology company that develops and commercializes therapies for pulmonary arterial hypertension (PAH) and other rare diseases. The company is a market leader in the PAH space, with a portfolio anchored by its treprostinil-based products, including Tyvaso DPI, Remodulin, and Orenitram, and is distinguished by its focus on the prostacyclin pathway and its vertically integrated manufacturing capabilities. The current investor narrative is overwhelmingly focused on the potential for significant market expansion following positive Phase 3 data for Tyvaso in a new lung disease indication, as reported in late March 2026, which has catalyzed a major re-rating of the stock and driven debate about the company's growth trajectory beyond its core PAH franchise.…
UTHR
United Therapeutics Corp
$548.27
Related headlines
Investment Opinion: Should I buy UTHR Today?
Rating & Thesis: Hold. UTHR is a high-quality, financially robust company with a transformative catalyst already priced in, presenting a balanced risk/reward profile at current levels. This aligns with the analyst consensus which is bullish but not euphoric, featuring an 'Equal Weight' rating from Wells Fargo alongside four Buy recommendations.
Supporting Evidence: The Hold rating is supported by a reasonable trailing P/E of 16.17x, industry-leading gross margins of 87.91%, and explosive free cash flow generation of $1.04 billion TTM. However, these strengths are counterbalanced by modest core revenue growth of 7.38% and elevated valuation ratios like the Price/Sales of 6.78x, which demands perfect execution on the Tyvaso launch. The stock's 90%+ rally over the past year suggests much of the near-term optimism is already reflected in the price.
Risks & Conditions: The thesis would upgrade to a Buy if the stock pulls back meaningfully (e.g., towards $500, offering a better entry point) or if early Tyvaso launch data exceeds expectations, confirming the growth story. It would downgrade to a Sell if the FDA approval process encounters significant delays or if Q4 2025 revenue growth decelerates further below 5%, signaling core business weakness. Based on the current data, the stock appears fairly valued to slightly overvalued relative to its near-term fundamentals, with its price anticipating future success that is not yet realized.
Sign up to view all
UTHR 12-Month Price Forecast
UTHR is a 'show me' story at its current valuation. The bullish thesis is compelling and backed by strong fundamentals, but the risk/reward is balanced after the massive rally. The stock is likely to trade sideways or with high volatility as the market digests FDA approval and early launch metrics. The stance would upgrade to Bullish on a pullback to the $500-$520 range, offering a better entry, or on confirmation of a blockbuster launch. It would turn Bearish if the FDA process stumbles or if the company fails to meet its own guidance for the core business in upcoming quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $712.75 and implied upside of +30.0% versus the current price.
Average Target
$712.75
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$439 - $713
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, suggesting this is not a widely followed large-cap name. The consensus sentiment appears bullish, as evidenced by recent institutional ratings which include four 'Buy' or 'Overweight' recommendations and one 'Equal Weight' from Wells Fargo, with no sell ratings. The average revenue estimate for the period is $6.19 billion, with a high estimate of $6.89 billion and a low of $5.65 billion, indicating a range of potential outcomes and a degree of uncertainty, likely tied to the commercial success of Tyvaso's potential label expansion. The wide spread between the high and low revenue estimates signals divergent views on the company's growth trajectory, with the high target likely pricing in successful market expansion for Tyvaso, while the low target may reflect a more conservative view on the core PAH business's growth potential.
Bulls vs Bears: UTHR Investment Factors
The evidence currently favors the bull case, primarily due to the transformative clinical catalyst for Tyvaso and the company's rock-solid financial foundation. The bear case is grounded in valuation concerns after a massive rally and the inherent risks of a binary, pipeline-dependent biotech. The single most important tension in the investment debate is the market's pricing of future Tyvaso expansion (evident in the 6.78x PS ratio) against the risk of commercial disappointment or regulatory delay. The resolution of this tension—through FDA decisions and early launch metrics—will determine whether the stock re-rates higher or experiences a significant multiple compression.
Bullish
- Exceptional Financial Fortress: UTHR operates with zero debt and holds $1.56 billion in cash, providing immense strategic flexibility. This pristine balance sheet, coupled with a trailing-twelve-month free cash flow of $1.04 billion, shields the company from market volatility and funds R&D without dilution.
- Transformative Clinical Catalyst: Positive Phase 3 data for Tyvaso in a new lung disease (reported March 2026) has already catalyzed a 90.8% one-year stock surge. This sets up a major FDA filing and potential market expansion beyond the core PAH franchise, which is the primary driver of the current bullish re-rating.
- Industry-Leading Profitability: The company boasts gross margins consistently above 87%, with Q4 2025 at 87.91%, demonstrating exceptional pricing power in its rare disease niche. This high-margin profile supports robust net income of $364.3 million in Q4 2025 and an operating margin of 47.67%.
- Reasonable Valuation Post-Surge: Despite the 90%+ price rally, the trailing P/E of 16.17x is not extreme historically, sitting between a past low of 8.75x and a high above 65x. The forward P/E of 17.18x suggests the market expects stable earnings growth, not irrational exuberance.
Bearish
- Extended Technical Price & Recent Weakness: The stock trades at $545.96, 90% of the way from its 52-week low to its high of $609.35, indicating it is extended. Recent 1-month performance of -5.79% shows profit-taking and consolidation, suggesting momentum may be stalling after the explosive rally.
- Modest Core Revenue Growth: Q4 2025 revenue growth was a steady but modest 7.38% YoY. Quarterly revenues have been range-bound between $677M and $799M for two years, indicating the core PAH business is mature and not a high-growth engine without the new Tyvaso indication.
- High Valuation on Sales & Cash Flow: The Price/Sales ratio of 6.78x and Price/Cash Flow ratio of 13.83x are elevated, pricing in significant future growth from Tyvaso's expansion. These multiples could compress if commercial uptake of the new indication disappoints or is delayed.
- Concentration & Pipeline Dependency: The company derives maximum revenue from Tyvaso DPI, creating product concentration risk. The entire investment thesis now hinges on the successful FDA approval and commercialization of Tyvaso for the new lung disease, with failure representing a major setback.
UTHR Technical Analysis
The stock is in a powerful, sustained uptrend, having gained 90.8% over the past year, significantly outperforming the broader market. As of the latest close at $545.96, the stock is trading near the top of its 52-week range, approximately 90% of the distance from its 52-week low of $272.12 toward its high of $609.35, indicating strong momentum but also suggesting the price is extended and potentially vulnerable to a pullback. The 1-month performance shows a -5.79% decline, which contrasts sharply with the 1-year surge, signaling a recent consolidation or profit-taking phase after the explosive rally triggered by the March 2026 clinical news; this short-term weakness, combined with a beta of 0.57, suggests the stock has exhibited lower volatility than the market during this recent pullback. Key technical support is at the 52-week low area near $272, while immediate resistance is at the 52-week high of $609.35; a decisive breakout above this high would signal a continuation of the primary bull trend, whereas a break below the recent consolidation range (approximately $540-$590) could indicate a deeper correction, though the low beta implies the stock's moves are generally less volatile than the S&P 500.
Beta
0.57
0.57x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$272-$609
Price range past year
Annual Return
+90.0%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | +1.5% |
| 3m | +3.4% | +13.4% |
| 6m | +8.1% | +10.9% |
| 1y | +90.0% | +24.5% |
| ytd | +10.4% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue growth is steady but modest, with Q4 2025 revenue of $790.2 million representing a 7.38% year-over-year increase, and quarterly revenues over the past two years have consistently ranged between $677 million and $799 million, indicating stable but not explosive top-line expansion. The company is highly profitable, with a robust net income of $364.3 million in Q4 2025 and industry-leading gross margins of 87.91% for that quarter, which have remained consistently above 87% for the last eight quarters, demonstrating exceptional pricing power and cost control within its niche therapeutic area. The balance sheet is exceptionally strong with zero debt (debt-to-equity of 0) and a substantial cash position of $1.56 billion as of Q4 2025, underpinned by robust free cash flow generation of $1.04 billion on a trailing-twelve-month basis and a high current ratio of 6.6, indicating ample liquidity to fund R&D and potential business development without external financing.
Quarterly Revenue
$790200000.0B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given the company's consistent profitability, the trailing P/E ratio of 16.17x is the primary valuation metric, with a forward P/E of 17.18x indicating the market expects roughly stable earnings growth. Compared to the broader biotechnology sector, which often trades at higher multiples for growth, UTHR's P/E appears reasonable, though a direct industry average is not provided in the data; its Price/Sales ratio of 6.78x and EV/EBITDA of 11.01x suggest the market values its stable cash flows and market leadership. Historically, the stock's own trailing P/E has fluctuated significantly, from a low near 8.75x in early 2024 to a high above 65x in early 2021 during a period of low earnings; the current multiple of 16.17x sits comfortably in the middle of this multi-year range, suggesting the stock is not at extreme historical valuation levels despite the recent price surge, as earnings have grown into the higher share price.
PE
16.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: United Therapeutics faces limited financial risk due to its zero debt and $1.56 billion cash position. The primary operational risk is revenue concentration, as the company derives maximum revenue from Tyvaso DPI, making it vulnerable to any disruption in that product's sales or pricing. Furthermore, while current profitability is robust with an 87.91% gross margin, the company's modest 7.38% YoY core revenue growth indicates dependence on the successful launch of Tyvaso's new indication to accelerate top-line expansion and justify its current sales multiple of 6.78x.
Market & Competitive Risks: The key market risk is valuation compression. The stock's 90.8% one-year surge has pushed it to trade at 90% of its 52-week range, with a PEG ratio of 1.16 suggesting growth is already priced in. If the Tyvaso launch underperforms lofty expectations, the elevated Price/Sales and EV/EBITDA (11.01x) multiples could contract sharply. Competitive risks in the PAH and broader lung disease space are ever-present, though the company's niche focus and proprietary delivery systems provide some defense. The stock's low beta of 0.57 suggests it has not moved in lockstep with the market during its rally, but this does not immunize it against sector-wide biotech de-ratings.
Worst-Case Scenario: The worst-case scenario involves the FDA rejecting or significantly delaying approval for Tyvaso's new indication, coupled with unexpected competitive pressure or pricing erosion in the core PAH business. This would shatter the growth narrative, leading to severe multiple compression and analyst downgrades. A realistic downside could see the stock retreat towards its 52-week low of $272.12, which would represent a loss of approximately -50% from the current price of $545.96. The recent maximum drawdown of -16.35% provides a gauge for near-term volatility, but a fundamental thesis break could drive a much deeper correction.
FAQ
The key risks are, in order of severity: 1) Regulatory/Clinical Risk: The entire investment thesis is leveraged to FDA approval and successful commercialization of Tyvaso for a new lung disease; a delay or rejection is the paramount risk. 2) Valuation Risk: The stock trades at 90% of its 52-week high with a PEG ratio of 1.16, leaving it vulnerable to a sharp pullback if growth expectations are not met. 3) Product Concentration Risk: The company derives maximum revenue from Tyvaso DPI, creating dependency on a single product franchise. 4) Growth Execution Risk: Core revenue growth is a modest 7.38%; the company must execute flawlessly on the new launch to justify its sales multiple.
The 12-month forecast for UTHR is a range of scenarios. The Base Case (50% probability) sees the stock trading between $540 and $609.35, as Tyvaso gains approval and launches meeting expectations. The Bull Case (30% probability) targets $609.35 to $700 on a stellar launch and multiple expansion. The Bear Case (20% probability) warns of a drop toward the 52-week low of $272.12 if the FDA process fails. The most likely outcome is the Base Case, predicated on the assumption that the company's strong financials and market position allow it to navigate a successful, albeit not explosive, launch, leading to consolidation near current levels.
UTHR appears fairly valued to slightly overvalued based on near-term fundamentals. Its trailing P/E of 16.17x is reasonable for a profitable biotech, but its Price/Sales ratio of 6.78x is elevated, indicating the market is pricing in significant future revenue growth from Tyvaso's label expansion. Compared to its own history, where the P/E has ranged from ~8.75x to over 65x, the current multiple is in a middle, fair range. The valuation implies the market expects successful FDA approval and a strong commercial launch for the new Tyvaso indication; any deviation from this path could lead to multiple compression.
UTHR is a good buy for investors seeking a financially robust company with a clear near-term catalyst, but timing is crucial. At the current price of $545.96, following a 90.8% one-year rally, much of the immediate upside from the positive Phase 3 data may already be priced in. The stock presents a favorable risk/reward for long-term holders who believe in the Tyvaso expansion story and can tolerate biotech volatility, but short-term traders may find better entry points on pullbacks. The lack of debt and strong cash flow provide a significant margin of safety, making it a relatively lower-risk biotech investment.
UTHR is more suitable for a long-term investment horizon of 2-3 years. While the FDA catalyst is near-term, the commercial ramp for the new Tyvaso indication and the realization of its full market potential will take multiple quarters. The stock's low beta of 0.57 and lack of a dividend make it less ideal for short-term trading or income seekers. Long-term investors can benefit from the company's cash flow generation, strategic use of its balance sheet, and the unfolding growth narrative, while weathering the inevitable volatility around clinical and regulatory milestones.
